eNeuro

Research Article: New Research | Disorders of the Nervous System

p11 in cholinergic interneurons of the nucleus accumbens is essential for dopamine responses to rewarding stimuli

Y. Hanada[1], Y. Kawahara[1], Y. N. Ohnishi[1], T. Shuto[1], M. Kuroiwa[1], N. Sotogaku[1], P. Greengard[2], Y. Sagi[2] and A. Nishi[1,2]

[1]*Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011 Japan*
[2]*Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065, USA*

https://doi.org/10.1523/ENEURO.0332-18.2018

Received: 27 August 2018

Revised: 4 October 2018

Accepted: 9 October 2018

Published: 19 October 2018

Author Contributions: KY, GP, SY and NA Designed Research; HY, KY, OYN, ST, KM, SN and SY Performed Research; HY, GP, SY and NA Wrote the Paper.

Funding: http://doi.org/10.13039/501100001691Japan Society for the Promotion of Science (JSPS)
16H05135

Funding: US Department of Defense-USAMRMC
W81XWH-16-1-0681
W81XWH-14-1-0130
W81XWH-09-1-0401

Funding: http://doi.org/10.13039/100007457JPB Foundation
#475

Funding: Black Family Foundation

The authors declare no competing financial interests.

Corresponding Author: Akinori Nishi, M.D., Ph.D., Department of Pharmacology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan. Tel: +81-942-317545; Fax: +81-942-317696; e-mail: nishia@med.kurume-u.ac.jp

Cite as: eNeuro 2018; 10.1523/ENEURO.0332-18.2018

p11 in cholinergic interneurons of the nucleus accumbens is essential for dopamine responses to rewarding stimuli.

Abbreviated tittle: p11 mediates dopamine responses to reward

Hanada Y[1], Kawahara Y[1], Ohnishi YN[1], Shuto T[1], Kuroiwa M[1], Sotogaku N[1], Greengard P[2], Sagi Y[2] and Nishi A[1,2]

[1]Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011 Japan.

[2]Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10065, USA.

Author Contributions: KY, GP, SY and NA Designed Research; HY, KY, OYN, ST, KM, SN and SY Performed Research; HY, GP, SY and NA Wrote the Paper.

Corresponding Author: Akinori Nishi, M.D., Ph.D.
Department of Pharmacology
Kurume University School of Medicine
67 Asahi-machi
Kurume, Fukuoka 830-0011, Japan
Tel: +81-942-317545
Fax: +81-942-317696
e-mail: nishia@med.kurume-u.ac.jp

Number of Figures: 7
Number of Tables: 2

Number of words for Abstract: 250
Number of words for Significance Statement: 115
Number of words for Introduction: 706
Number of words for Discussion: 1109

Acknowledgements: This research was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science to A.N. (16H05135), and grants from US Department of Defense- USAMRMC to P.G. (W81XWH-16-1-0681), W81XWH-14-1-0130 and W81XWH-09-1-0401 to Y.S., JPB Foundation to P.G. (#475) and the Black Family Foundation to P.G.

Conflict of interest: The authors declare no competing financial interests.

Abstract

A recent study showed that p11 expressed in cholinergic interneurons (CINs) of the nucleus accumbens (NAc) is a key regulator of depression-like behaviors. Dopaminergic neurons projecting to the NAc are responsible for reward-related behaviors, and their function is impaired in depression. The present study investigated the role of p11 in NAc CINs in dopamine responses to rewarding stimuli. The extracellular dopamine and acetylcholine (ACh) levels in the NAc were determined in freely moving male mice using *in vivo* microdialysis. Rewarding stimuli (cocaine, palatable food and female mouse encounter) induced an increase in dopamine efflux in the NAc of wild-type mice. The dopamine responses were attenuated (cocaine) or abolished (food and female mouse encounter) in constitutive p11 KO mice. The dopamine response to cocaine was accompanied by an increase in ACh NAc efflux, whereas the attenuated dopamine response to cocaine in p11 KO mice was restored by activation of nicotinic or muscarinic ACh receptors in the NAc. Dopamine responses to rewarding stimuli and ACh release in the NAc were attenuated in mice with deletion of p11 from cholinergic neurons (ChAT-p11 cKO mice), whereas gene delivery of p11 to CINs restored the dopamine responses. Furthermore, chemogenetic studies revealed that p11 is required for activation of CINs in response to rewarding stimuli. Thus**,** p11 in NAc CINs plays a critical role in activating these neurons to mediate dopamine responses to rewarding stimuli. The dysregulation of mesolimbic dopamine system by dysfunction of p11 in NAc CINs may be involved in pathogenesis of depressive states.

Significance Statement

p11 is a critical regulator of CIN activity as measured by the dopamine response of the mesolimbic dopamine pathway to rewarding stimuli. p11 is required for reward-mediated NAc CIN activation and induction in ACh release, resulting in the enhancement of dopamine release. The reduction of p11 expression in NAc CINs is tightly associated with anhedonia as well as other depression-like symptoms of behavioral despair. To improve therapeutic efficacy of antidepressants for anhedonia, a new type of antidepressant directly or indirectly acting on the mesolimbic dopamine pathway needs to be developed.

71 For this purpose, therapeutic strategies that increase the function of p11 and its signaling pathway in
72 NAc CINs may have an impact on antidepressant efficacy.
73

Introduction

Depressive patients show a variety of mood-related symptoms: increased negative affect (*e.g.*, depressed mood, guilt, anxiety) and decreased positive affect [e.g., anhedonia (loss of interest or pleasure), decreased motivation] (Clark and Watson, 1991). Although antidepressants, which upregulate serotonin and/or noradrenaline neurotransmission, effectively alleviate negative affect, they are relatively ineffective at improving positive affect (Shelton and Tomarken, 2001; Craske et al., 2016). The ineffectiveness can be explained by the fact that anhedonia is associated with a deficit in the dopamine reward circuit (Der-Avakian and Markou, 2012; Russo and Nestler, 2013). Since anhedonia is a predictor of poor long-term outcomes including poor treatment response and suicide (Craske et al., 2016), further understanding of the neurobiology of anhedonia in depression is required to improve therapeutic efficacy of current antidepressant treatments.

p11 (S100A10) is a member of the S100 EF-hand protein family, and is known to play pivotal roles in the pathophysiology of depression (Svenningsson et al., 2006; Svenningsson et al., 2013). Extensive studies on the function of p11 revealed that p11 potentiates serotonin neurotransmission via multiple mechanisms including recruitment of 5-HT_{1B} and 5-HT_4 receptors at the cell surface (Svenningsson et al., 2006; Warner-Schmidt et al., 2009), and regulates depression-like behaviors and responses to antidepressants (Svenningsson et al., 2013; Medrihan et al., 2017). Constitutive p11 knockout (KO) mice show depression-like behaviors, including increased behavioral despair and anhedonia (Svenningsson et al., 2006; Warner-Schmidt et al., 2009; Alexander et al., 2010). p11 is expressed in various brain regions (Milosevic et al., 2017), and p11 expressed in the nucleus accumbens (NAc) (Alexander et al., 2010; Warner-Schmidt et al., 2012), cerebral cortex (Schmidt et al., 2012; Seo et al., 2017b), hippocampus (Egeland et al., 2010; Oh et al., 2013; Medrihan et al., 2017) and habenula (Seo et al., 2017a) affects depression-like behaviors via a variety of neural mechanisms. Furthermore, in depressed patients, the expression of p11 is reduced in the anterior cingulate cortex and NAc (Svenningsson et al., 2006; Alexander et al., 2010).

The NAc receives dopaminergic input from the ventral tegmental area (VTA) and has been implicated as a key brain region of the reward system (Russo and Nestler, 2013; Hu, 2016). In the NAc,

p11 is expressed in a cell-type specific manner: low levels in medium spiny neurons (MSNs) and high levels in cholinergic interneurons (CINs) (30-fold higher than non-cholinergic neurons) (Warner-Schmidt et al., 2012). p11 in CINs has been shown to be a key regulator of depression-like behavior: (1) mice with p11 knockdown in NAc show depression-like behaviors (Alexander et al., 2010) and (2) p11 knockout mice in choline acetyltransferase (ChAT) cells (ChAT-p11 cKO mice) show depression-like behaviors and the behaviors are rescued by overexpression of p11 in NAc CINs (Warner-Schmidt et al., 2012).

Cholinergic tone in the mesolimbic dopamine system plays an important role in behavioral responses to psychostimulants and natural reward (Hoebel et al., 2007; Williams and Adinoff, 2008). In the NAc, psychostimulants increase the activity of CINs (Berlanga et al., 2003; Witten et al., 2010) and ACh release (Consolo et al., 1999). Feeding induces a gradual increase in ACh, which is known to have a role in the onset of satiation (Hoebel et al., 2007). Effects of cholinergic neurotransmission on responses to psychostimulants and natural reward-related behaviors are highly dependent on physiological and experimental conditions (Consolo et al., 1999; Gonzales and Smith, 2015) and contradictory (Hikida et al., 2001; Hoebel et al., 2007; Witten et al., 2010; Grasing, 2016). Graising et al. proposed a threshold model to explain the inverted U-shape dose response of ACh, in which moderate activation of CINs increases the reward probability, whereas activation of CINs above a certain threshold reduces it (Grasing, 2016).

p11 KO mice show altered cocaine conditional place preference (CPP) (Arango-Lievano et al., 2014; Thanos et al., 2016), suggesting that p11 plays a pivotal role in the regulation of reward. However, a role for p11 in NAc dopamine neurotransmission has not been established. Therefore, we investigated the role of p11 in dopamine neurotransmission in the NAc and prefrontal cortex (PFC) after exposing mice to cocaine or to natural rewards. The present study demonstrates that p11 is required to activate CINs to increase ACh release in response to rewarding stimuli in the NAc, leading to activation of the mesolimbic (VTA-NAc) dopamine system.

Materials and methods

Animals

Male constitutive p11 KO (Svenningsson et al., 2006), ChAT-Cre (GENSAT, GM60) and ChAT-p11 cKO (Warner-Schmidt et al., 2012) mice at 8-12 weeks of age were used. ChAT-p11 cKO mice were generated by breeding floxed p11 mice with ChAT-Cre mice (Warner-Schmidt et al., 2012). Mice were housed 2-5 per cage and maintained on a 12-h light/dark cycle (lights on from 7:00 am to 7:00 pm) with access to standard mouse chow and water ad libitum. All mice used in this study were handled in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the US National Institutes of Health, and the specific protocols were approved by the Institutional Animal Care and Use Committee. All efforts were made to minimize the number of animals used.

Drugs

Cocaine (Takeda Pharmaceutical companies, Osaka, Japan), nicotine (Sigma-Aldrich, St. Louis, MO), oxotremorine (Sigma-Aldrich), dihydro-ß-erythroidin (DHßE; Sigma-Aldrich), atropine (Sigma-Aldrich) and clozapine N-oxide (CNO; Cayman Chemical, Ann Arbor, MI) were dissolved in Ringer's solution for local infusion.

Surgery and brain dialysis

Microdialysis was performed with an I-shaped cannula. Microdialysis probes were implanted in the unilateral NAc (exposed length 1.5 mm) or PFC (exposed length 3.5 mm) of 12-week-old mice under pentobarbital (50 mg/kg i.p.) and xylazine (8 mg/kg i.p.) anesthesia and local application of 10% lidocaine. The coordinates of the implantation into the NAc were A/P +1.4 mm, L/M 0.6 mm from the Bregma and V/D 4.5 mm from the dura at an angle of 0° in the coronal plane (Figure 1a). The coordinates of the implantation into the PFC were A/P +1.9 mm, L/M 0.3 mm from the bregma and V/D 2.8 mm from the dura at an angle of 0° in the coronal plane (Figure 1b). After surgery, the mice were housed individually in plastic cages (30×30×40 cm).

Microdialysis experiments were conducted 24-48 h after implantation of the probe, as

previously described (Kaneko et al., 2016). An on-line approach for real-time quantification of dopamine was used, in which the probes were perfused with Ringer's solution at a flow rate of 2.0 µl/min. The 20 min sample fractions collected through dialysis probes were directly injected to high-performance liquid chromatography using a reverse-phase column (150×4.6 mm; Supelco LC18, Bellefonte, PA) with electrochemical detection. An EP-300 pump (EICOM, Kyoto, Japan) was used in conjunction with an electrochemical detector (potential of the first cell, +180 mV; potential of the second cell, -180 mV) (ESA, Chelmsford, MA). The mobile phase was a mixture of 4.1 g/L sodium acetate adjusted to pH 5.5, 50 mg/L Na_2EDTA, 140 mg/L octanesulfonic acid and 10% methanol. The flow rate was 0.4 ml/min. The detection limit of assay was about 0.3 fmol per sample (on-column). The composition of the Ringer's solution (in mM) was: NaCl 140.0, KCl 4.0, $CaCl_2$ 1.2, and $MgCl_2$ 1.0. At the end of the experiment, the mice were given an overdose of sevoflurane and brains were fixed with 4% paraformaldehyde via intracardiac infusion. Coronal sections (50 µm) were cut and dialysis probe placement was localized using the atlas of Paxinos and Franklin (Paxinos and Franklin, 2001) as reference. Mice in which dialysis probes were misplaced, were not included in data analysis.

For analysis of ACh, the microdialysis probes were perfused with Ringer's solution at a flow rate of 1.0 µl/min. The 10 min dialysate fractions were collected, and ACh content was detected using HPLC-ECD system with AC-GEL separation column (2.0 ID X 150 mm) with a platinum working electrode (Eicom-USA, CA) as previously reported (Virk et al., 2016). ACh content in each dialysate sample was determined using subsequent standards with known amounts of ACh. The threshold for detection was 2.44 fmol/min ACh. Neostigmine (100 nM) was added to the dialysis solution to establish continuous ACh efflux.

ChAT cell-specific expression of p11, rM4D(Gi-DREADD) and rM3D(Gs-DREADD) using AAV vectors

For overexpression of p11 in ChAT cells of the NAc in ChAT-p11 cKO mice, *AAV-loxP-RFP/stop-loxP-p11* (2.7×10^{12} virus molecules/ml) and its control vector, *AAV-loxP-RFP/stop-loxP-YFP* (5.2×10^{12} virus molecules/ml), were used (Warner-Schmidt et al., 2012).

RFP was expressed in Cre recombinase-negative cells such as MSNs, and p11 or YFP was expressed in ChAT cells of the NAc, where the Cre recombinase was expressed under control of ChAT promoter.

For chemogenetic modulation of ChAT cell functions, *rAAV2/hsyn-DIO-rM3D(Gs)-mCherry* (6.6×10^{12} virus molecules/ml), *rAAV2/hsyn-DIO-rM4D(Gi)-mCherry* (3.7×10^{12} virus molecules/ml) and its control vector, *rAAV2/Ef1a-DIO-mCherry* (3.2×10^{12} virus molecules/ml), purchased from University of North Carolina (UNC) Vector Core, were used.

Viruses were infused bilaterally into the NAc in ChAT-p11 cKO mice at 8 weeks old, under pentobarbital (50 mg/kg i.p.) and xylazine (8 mg/kg i.p.) anesthesia and local application of 10% lidocaine. The coordinates of the infusions into the NAc were A/P +1.4 mm, L/M ±0.6 mm from the bregma, and V/D 3.7 mm from the dura at an angle of 0° in the coronal plane. All infusions were performed using a 5 µl Hamilton syringe with a 33 G needle attached at a rate of 0.1 µl/min. To prevent reflux after infusion, the injection needle was left in the place for 15 min. The needle was withdrawn a short distance (0.3 mm) every 3 min, and this procedure was repeated until the needle was completely removed. Four weeks later, the microdialysis probe was implanted and *in vivo* microdialysis assessments were performed.

Rewarding stimuli

Cocaine infusion: Cocaine infusion at 1 µM into the NAc induced the increase of extracellular dopamine (150-200 % of basal level), which is similar to the increase of dopamine in the NAc induced by systemic cocaine administration (at low to moderate doses) with rewarding effects (Brown et al., 1991; Tourino et al., 2012). During the experimental period, cocaine at 1 µM was infused into the NAc or PFC through the dialysis membrane for 140 min after obtaining three stable consecutive samples of dopamine differing by <10%.

Palatable food: After microdialysis probe implantation, flavored serial food (Asahi Food & Healthcare Co., Tokyo, Japan), to which mice exhibit palatability, was introduced to the mice in the acrylic box 24 h before the start of the experiment to promote habituation (Kawahara et al., 2013). Flavored serial food was removed 1 h before the start of experiments on the day of the experiments, whereas mice had free

access to regular food. During the experimental period, after obtaining three stable consecutive samples of dopamine, regular food was removed and then mice were exposed to palatable food for 20 min.

Exposure to a female mouse: During the experimental period, male mice were exposed to female C57BL/6N mice at the same age, purchased from Japan SLC (Shizuoka, Japan), after obtaining three stable consecutive samples of dopamine. Female mice enclosed in a clear acrylic cage (10×10×20 cm) with 1 cm slits were placed in the plastic cage (30×30×40 cm) of male mouse for 20 min, and thereafter the female mouse and the clear acrylic cage were removed.

Immunohistochemistry

Mice were deeply anesthetized with sodium pentobarbital and transcardially perfused with 4% paraformaldehyde in phosphate buffer (0.1 M, pH 7.4). Three to four hours after perfusion, the brains were removed and further fixed with 4% paraformaldehyde overnight at 4˚C. Coronal sections of the NAc (50 μm in thickness) were cut with a vibrating blade microtome (VT1000S, Leica Microsystems, Nussloch, Germany). Sections were processed for immunohistochemistry using the free-floating method, as described previously (Fukuda et al., 1996). Sections were incubated with a goat anti-p11 (S100A10) antibody (Cat# AF2377, RRID:AB_2183469; 1:200 dilution; R&D Systems, Minneapolis, MN) or a goat anti-ChAT antibody (Cat# AB144P, RRID:AB_2079751; 1:500 dilution; Millipore, Temecula, CA) for 1 week at 20°C. Antibody binding was visualized with Alexa Fluor 488 or 647-conjugated donkey anti-goat IgG (1:800 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA). Sections were mounted using antifade media (Vectashield; Vector Laboratories, Burlingame, CA) and examined with a confocal laser-scanning microscope, LSM 5 PASCAL (Zeiss, Oberkochen, Germany) or FV-1000 (Olympus, Tokyo, Japan).

Statistical Analysis

The data are displayed as the mean ± S.E.M. For analyses of microdialysis data, all values were expressed as a percentage of the basal values (100%) for each group, obtained as the average of three and six stable baseline samples for dopamine and ACh, respectively. The values obtained after rewarding

stimuli were compared with the basal values using mixed linear models with time as a covariate, and Bonferroni's correction was applied for multiple comparisons using the SAS MIMED procedure (Version 9.4, SAS Institute, Cary, NC, USA). Repeated measures two-way ANOVA were used to compare the experimental groups (JMP Pro, SAS Institute). The basal values of dopamine and/or its metabolites were compared with unpaired Student's *t*-test (Table 1), and the effects of clozapine-N-oxide (CNO) on dopamine levels in ChAT-p11 cKO mice with Gs DEADD viral injection were compared with one-way ANOVA followed by Neuman-Keuls post hoc test (Figure 6b). The analyses were performed using Prism 5.0 software (GraphPad, San Diego, CA, USA). $p < 0.05$ was considered to be significant. Details of the statistical analysis are listed in Table 2.

Results

Dopamine responses to rewarding stimuli in the NAc and PFC of constitutive p11 KO mice

The levels of dopamine in the NAc in response to a drug of abuse, cocaine, and exposure to natural rewarding stimuli, a palatable food or female mouse, were determined with *in vivo* microdialysis. The basal extracellular levels of dopamine and its metabolites [3,4-dihydroxy-phenylacetic acid (DOPAC) and homovanillic acid (HVA)] in the NAc and PFC were similar between wild-type (WT) and constitutive p11 KO (p11 KO) mice (Table 1). Cocaine infusion (1 μM) into the NAc increased the levels of dopamine to 150% of control in the NAc of WT mice, but the dopamine response to cocaine infusion was largely attenuated in p11 KO mice (Figure 1c). Exposure to a palatable food or female mouse increased the dopamine levels similarly to cocaine infusion in the NAc of WT mice (Figure 1d-e). The dopamine response to the palatable food or female mouse was abolished in the NAc of p11 KO mice. In the PFC, all the rewarding stimuli increased the dopamine levels to the same extent in WT and p11 KO mice (Figure 1f-h). These results indicate that p11 is selectively involved in the regulation of the mesolimbic (VTA-NAc) dopamine system, but not in the regulation of the mesocortical (VTA-PFC) dopamine system.

Effects of a nicotinic or muscarinic receptor agonist on the attenuated dopamine response to cocaine in the NAc of constitutive p11 KO mice

p11 is highly expressed in NAc CINs (Warner-Schmidt et al., 2012) and is involved in the regulation of ACh release (Virk et al., 2016). In addition, ACh has been shown to stimulate dopamine release via activation of α4β2 nicotinic ACh receptors (nAChRs) (Wonnacott et al., 2000; Hamada et al., 2004) and M5 muscarinic receptors (Bendor et al., 2010; Kuroiwa et al., 2012) at dopaminergic axon terminals. These observations suggest that p11 regulates mesolimbic dopamine release by regulating cholinergic signaling at dopaminergic axon terminals We therefore investigated whether activation of nAChRs or muscarinic receptors could restore the dopamine responses to cocaine in the NAc of p11 KO mice (Figure 2a-b). When cocaine was co-infused into the NAc (1 μM) with either nicotine (1 μM) or the non-selective muscarinic receptor agonist, oxotremorine (0.1 μM), it was able to increase the dopamine

levels in the NAc of p11 KO mice, similarly to those of WT mice. Infusion of either nicotine (1 μM) or oxotremorine (0.1 μM) alone did not affect the levels of dopamine in the NAc of WT or p11 KO mice. These results suggest that lack of p11 may reduce ACh release and ACh-mediated effects, resulting in the attenuation of the dopamine responses to cocaine in the NAc of p11 KO mice.

Role of p11 in NAc CINs in the dopamine responses to rewarding stimuli

To directly investigate the role of p11 in choline acetyltransferase (ChAT) expressing cells, the dopamine responses to rewarding stimuli were evaluated in the NAc of ChAT cell-specific p11 KO mice (ChAT-p11 cKO mice), which were obtained by mating p11 floxed mice with ChAT-Cre mice (Warner-Schmidt et al., 2012). The basal extracellular levels of dopamine in the NAc were not affected by deletion of p11 in ChAT cells (Table 1). Cocaine infusion (1 μM) into the NAc or exposure to a palatable food or female mouse increased the extracellular levels of dopamine in the NAc of control mice (ChAT-Cre$^{-/-}$ p11$^{flox/flox}$ mice) (Figure 3). The dopamine responses to the rewarding stimuli were attenuated or completely abolished in the NAc of ChAT-p11 cKO mice (ChAT-Cre^{+} p11$^{flox/flox}$ mice). These results indicate that p11 in ChAT cells plays a critical role in the dopamine responses to rewarding stimuli.

ChAT-positive cells or axon fibers in the NAc correspond to CINs, and therefore p11 in NAc CINs likely regulates the dopamine responses. However, there is a possibility that p11 expressed in ChAT cells of other brain regions such as basal forebrain cholinergic neurons and pontomesencephalic cholinergic neurons may indirectly affect the VTA-NAc dopamine system. To rule out this possibility, p11 was overexpressed in CINs by injecting *AAV-loxP-RFP/stop-loxP-p11* (*AAV-p11*) in the NAc of ChAT-p11 cKO mice (Warner-Schmidt et al., 2012), and the dopamine responses to rewarding stimuli were evaluated. Injection of p11 overexpressing virus (*AAV-p11*) into the NAc induced the expression of RFP in ChAT-Cre$^{-/-}$ cells such as medium-sized spiny neurons and GABAergic interneurons (Figure 4a). In ChAT-Cre^{+} cells, p11 was expressed in RFP-negative large-sized neurons. As control virus, *AAV-loxP-RFP/stop-loxP-YFP* (*AAV-YFP*) was injected into the NAc. YFP expression induced by ChAT-Cre was indeed observed in RFP-negative ChAT expressing

299 cells (Figure 4b). These immunohistochemical analyses revealed that p11 is selectively overexpressed in
300 NAc CINs. Overexpression of p11, but not of YFP, in NAc CINs restored the dopamine responses to
301 rewarding stimuli in the NAc of ChAT-p11 cKO mice (Figure 4c-e). These results suggest that NAc
302 CINs have the ability to regulate the mesolimbic dopamine reward system via p11-dependent
303 mechanisms.
304
305 **Role of p11 in NAc CINs in the cocaine-induced ACh release**
306 Pharmacological analyses suggested that p11 in NAc CINs is required for the dopamine responses to
307 rewarding stimuli presumably via mechanisms involving ACh release from CINs and activation of
308 dopaminergic terminals by ACh. We therefore measured the extracellular levels of ACh after cocaine
309 infusion in the NAc of WT and ChAT-p11 cKO mice (Figure 5). Cocaine infusion (1 μM) into the NAc
310 increased the levels of ACh to 130-140% of control in the NAc of WT mice, but failed to increase them
311 in the NAc of ChAT-p11 cKO mice. These results confirm that cocaine induces the release of ACh from
312 CINs and that p11 is essential for the cocaine-induced release of ACh. It is likely that the released ACh
313 together with the inhibition of dopamine transporter by cocaine increases the extracellular levels of
314 dopamine in the NAc.
315
316 **Effects of chemogenetic activation of NAc CINs on the dopamine responses to cocaine in**
317 **ChAT-p11 cKO mice.**
318 Our studies using p11 KO and ChAT-p11 cKO mice with pharmacological and viral tools strongly
319 suggested that cholinergic regulation of dopamine release is attenuated following deletion of p11 in NAc
320 CINs. Next we investigated whether chemogenetic activation of NAc CINs may restore the attenuated
321 dopamine responses to cocaine in ChAT-p11 cKO mice. Gs-DREADD (*AAV-DIO-rM3D(Gs)-mCherry*)
322 or control (*AAV-DIO-mCherry*) virus was injected into the NAc of ChAT-p11 cKO mice. After 4 weeks
323 of Gs-DREADD viral injection, mCherry was expressed in ChAT-positive large-sized neurons in the
324 NAc (Figure 6a), suggesting the expression of rM3D(Gs) in CINs. Clozapine-N-oxide (CNO) was
325 locally infused into the NAc via the microdialysis probe. CNO infusion of 3 μM did not affect the basal

levels of dopamine in ChAT-p11 cKO mice with Gs-DREADD viral injection (Figure 6b). CNO infusion at a higher concentration (10 μM) increased the average of dopamine levels at 40, 60 and 80 min of CNO infusion in the NAc of ChAT-p11 cKO mice with Gs-DREADD viral injection, but not with control viral injection. These results suggest that chemogenetic activation of CINs alone induces the release of dopamine in the NAc, only when a high concentration of CNO (10 μM) was infused.

We next evaluated the effects of chemogenetic activation of CINs on the dopamine responses to cocaine. After observing that CNO infusion (3 μM) for 140 min did not affect the basal levels of dopamine, cocaine infusion (1 μM) into NAc was started. Cocaine infusion together with CNO infusion (3 μM) induced the dopamine responses in the NAc of ChAT-p11 cKO mice with Gs-DREADD viral injection (Figure 6c). Restoration of dopamine responses was not achieved in animals treated with Gs-DREADD plus cocaine without CNO or in animals treated with mCherry plus cocaine/CNO. These results suggest that activation of CINs is required for dopamine responses to rewarding stimuli in the NAc, and that p11 is essential for CIN activation.

Effects of chemogenetic inhibition of NAc CINs on the dopamine responses to cocaine in control mice.

We further investigated whether the inhibition of NAc CINs by Gi-DREADD could suppress the dopamine response to cocaine infusion in the NAc of ChAT-Cre mice injected with Gi-DREADD virus (*AAV-DIO-rM4D(Gi)-mCherry*) or control virus (*AAV-DIO-mCherry*). In ChAT-Cre mice expressing Gi-DREADD, CNO infusion (3 μM) into the NAc attenuated the dopamine response to cocaine infusion (1 μM). CNO infusion into the NAc of ChAT-Cre mice without Gi-DREADD expression did not affect the dopamine response to cocaine infusion.

Discussion

In this study, we demonstrated that p11 expressed in CINs of the NAc is a critical regulator of the dopamine reward system. *In vivo* microdialysis analyses in constitutive p11 KO mice revealed that lack of p11 induced the attenuation of dopamine responses to rewarding stimuli including a drug of abuse and natural rewards. The attenuation of the dopamine responses in the mesolimbic (VTA-NAc) dopamine system, but not in the mesocortical (VTA-PFC) dopamine system, suggested the importance of p11 in the NAc. The dopamine responses were attenuated in ChAT-p11 cKO mice, and the attenuated responses were restored by the overexpression of p11 in NAc CINs, indicating the critical role of p11 in NAc CINs. Furthermore, lack of p11 in NAc CINs results in the attenuation of ACh release in response to cocaine and the subsequent decrease in nicotinic and muscarinic ACh receptor signaling at dopaminergic terminals, leading to the suppressed dopamine responses to cocaine and possibly other rewarding stimuli. The function of p11 in CINs was confirmed by the chemogenetic studies: CIN activation by Gs-DREADD restored the dopamine responses in ChAT-p11 cKO mice, whereas CIN inhibition by Gi-DREADD suppressed the dopamine response in control (ChAT-Cre) mice. Thus, p11 in NAc CINs is required for the dopamine response of the mesolimbic rewarding system. These findings provide insights into the neural mechanisms of anhedonia in depression.

Selective regulation of the mesolimbic dopamine pathway by p11

p11 regulates the dopamine response to rewarding stimuli in the mesolimbic dopamine pathway, but not in the mesocortical dopamine pathway. Selective regulation of the mesolimbic dopamine pathway is enabled by action of p11 in CINs of the NAc. PFC receives cholinergic innervation from the basal forebrain (Ballinger et al., 2016), and ChAT cells in the basal forebrain also express p11 (Milosevic et al., 2017). Although p11 in ChAT cells of the basal forebrain is deleted in ChAT-p11 cKO mice, the deletion of p11 did not alter the dopamine response in the mesocortical dopamine pathway. A possible role for p11 in the cholinergic neurons of the basal forebrain needs to be explored in other brain functions such as cognition (Ballinger et al., 2016). Furthermore, the fact that the lack of p11 in VTA dopamine neurons of p11 null mice did not affect the dopamine responses in the mesocortical dopamine pathway suggests a

limited role for p11 in regulating the activity of the dopaminergic neurons of the VTA. In fact, this interpretation is consistent with the low expression of p11 in the VTA (Milosevic et al., 2017). Thus, p11 in CINs is a critical regulator of the dopamine response to rewarding stimuli in the mesolimbic dopamine pathway.

Functional role of p11 in the regulation of CIN activity and ACh release in the NAc

Cholinergic tone in the mesolimbic dopamine system plays an important role in behavioral responses to psychostimulants and natural reward (Hoebel et al., 2007; Williams and Adinoff, 2008). It has been demonstrated that silencing CIN activity induces depression-like behaviors and that p11 in NAc CINs shows antidepressant effects (Warner-Schmidt et al., 2012). Our findings indicate that, in the NAc, activation of CINs and the subsequent release of ACh are required for dopamine responses to rewarding stimuli, and that p11 is essential for CIN activation in response to reward. It is likely that ACh released from CINs in a p11-dependent manner activates the dopamine release machinery via activation of α4β2 nAChRs (Wonnacott et al., 2000; Hamada et al., 2004) and M5 muscarinic receptors (Bendor et al., 2010; Kuroiwa et al., 2012) at dopaminergic axon terminals, leading to the enhancement of the increase in extracellular dopamine induced by cocaine, a dopamine reuptake inhibitor. Furthermore, p11-dpenendent activation of CINs and ACh release seems to be optimal to enhance the dopamine reward probability, because the inverted U-shape threshold model suggests that activation of CINs above a certain threshold reduces it (Grasing, 2016). This is in line with a previous report that basal ACh release is unchanged in ChAT-p11 cKO mice (Virk et al., 2016). Interaction of p11 with its binding proteins such as the 5-HT_{1B} receptor, 5-HT_4 receptor and mGluR5 are required for antidepressant action (Svenningsson et al., 2006; Warner-Schmidt et al., 2009; Lee et al., 2015), but the precise p11-mediated mechanisms for CIN activation were unknown. The interaction of p11 with 5-HT_{1B} receptors in CINs may induce the inhibition of CIN activity (Virk et al., 2016), but this mechanism cannot explain our findings. Future studies should determine the molecular mechanisms by which p11 and presumably the p11 complex may activate CINs.

Role of p11 in CINs of the NAc in anhedonic behaviors of depression

Anhedonia is a core symptom of depression. It has been shown that anhedonia is associated with a deficit in the mesolimbic dopamine circuit (Der-Avakian and Markou, 2012; Russo and Nestler, 2013). Current antidepressants are relatively ineffective for treating anhedonia (Craske et al., 2016), probably because depressive patients are treated with antidepressants primarily acting on 5-HT and/or noradrenaline transmission (Dunlop and Nemeroff, 2007). To develop a new type of antidepressant effective for anhedonia, it is extremely important to elucidate the mechanism by which the mesolimbic dopamine reward circuit is dysregulated in depression. In this study, we clearly demonstrated that p11 in NAc CINs is a critical regulator of the mesolimbic dopamine response to rewarding stimuli. The findings suggest that p11, which is required for activation of CINs and the ACh release in response to rewarding stimuli, plays a pivotal role in the pathophysiology of anhedonia in depression (Svenningsson et al., 2006).

Deletion of p11 in ChAT cells, p11 knockdown in the NAc or silencing NAc CINs induces anhedonic behavior, and overexpression of p11 in NAc CINs reverses anhedonic behavior in constitutive p11 KO mice (Alexander et al., 2010; Warner-Schmidt et al., 2012). In addition, p11 expression in the NAc is reduced in depressed patients (Svenningsson et al., 2006; Alexander et al., 2010). Thus, the reduction of p11 expression in NAc CINs is tightly associated with anhedonia as well as other depression-like symptoms of behavioral despair. Therapeutic strategies that increase the expression of p11 and the signaling of the p11 complex in NAc CINs may have impact on current antidepressant treatment.

In conclusion, p11 is a critical regulator of CIN activity as measured by the dopamine response of the mesolimbic dopamine pathway to rewarding stimuli. p11 is required for reward-mediated NAc CIN activation and induction in ACh release, resulting in the enhancement of dopamine release. To improve therapeutic efficacy of antidepressants for anhedonia, a new type of antidepressant directly or indirectly acting on the mesolimbic dopamine pathway needs to be developed. For this purpose, p11 and its complex in the NAc CINs may be good therapeutic targets.

References

Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, Vernov M, Stavarache M, Musatov S, Flajolet M, Svenningsson P, Greengard P, Kaplitt MG (2010) Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2:54ra76.

Arango-Lievano M, Schwarz JT, Vernov M, Wilkinson MB, Bradbury K, Feliz A, Marongiu R, Gelfand Y, Warner-Schmidt J, Nestler EJ, Greengard P, Russo SJ, Kaplitt MG (2014) Cell-type specific expression of p11 controls cocaine reward. Biol Psychiatry 76:794-801.

Ballinger EC, Ananth M, Talmage DA, Role LW (2016) Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron 91:1199-1218.

Bendor J, Lizardi-Ortiz JE, Westphalen RI, Brandstetter M, Hemmings HC, Jr., Sulzer D, Flajolet M, Greengard P (2010) AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release. EMBO J 29:2813-2826.

Berlanga ML, Olsen CM, Chen V, Ikegami A, Herring BE, Duvauchelle CL, Alcantara AA (2003) Cholinergic interneurons of the nucleus accumbens and dorsal striatum are activated by the self-administration of cocaine. Neuroscience 120:1149-1156.

Brown EE, Finlay JM, Wong JT, Damsma G, Fibiger HC (1991) Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse. J Pharmacol Exp Ther 256:119-126.

Clark LA, Watson D (1991) Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol 100:316-336.

Consolo S, Caltavuturo C, Colli E, Recchia M, Di Chiara G (1999) Different sensitivity of in vivo acetylcholine transmission to D1 receptor stimulation in shell and core of nucleus accumbens. Neuroscience 89:1209-1217.

Craske MG, Meuret AE, Ritz T, Treanor M, Dour HJ (2016) Treatment for Anhedonia: A Neuroscience Driven Approach. Depress Anxiety 33:927-938.

Der-Avakian A, Markou A (2012) The neurobiology of anhedonia and other reward-related deficits.

458 Trends Neurosci 35:68-77.
459 Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen
460 Psychiatry 64:327-337.
461 Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P (2010) Neurogenic effects of fluoxetine are
462 attenuated in p11 (S100A10) knockout mice. Biol Psychiatry 67:1048-1056.
463 Fukuda T, Aika Y, Heizmann CW, Kosaka T (1996) Dense GABAergic input on somata of
464 parvalbumin-immunoreactive GABAergic neurons in the hippocampus of the mouse. Neurosci
465 Res 26:181-194.
466 Gonzales KK, Smith Y (2015) Cholinergic interneurons in the dorsal and ventral striatum: anatomical
467 and functional considerations in normal and diseased conditions. Ann N Y Acad Sci 1349:1-45.
468 Grasing K (2016) A threshold model for opposing actions of acetylcholine on reward behavior:
469 Molecular mechanisms and implications for treatment of substance abuse disorders. Behav Brain
470 Res 312:148-162.
471 Hamada M, Higashi H, Nairn AC, Greengard P, Nishi A (2004) Differential regulation of dopamine D1
472 and D2 signaling by nicotine in neostriatal neurons. J Neurochem 90:1094-1103.
473 Hikida T, Kaneko S, Isobe T, Kitabatake Y, Watanabe D, Pastan I, Nakanishi S (2001) Increased
474 sensitivity to cocaine by cholinergic cell ablation in nucleus accumbens. Proc Natl Acad Sci U S
475 A 98:13351-13354.
476 Hoebel BG, Avena NM, Rada P (2007) Accumbens dopamine-acetylcholine balance in approach and
477 avoidance. Curr Opin Pharmacol 7:617-627.
478 Hu H (2016) Reward and Aversion. Annu Rev Neurosci 39:297-324.
479 Kaneko F, Kawahara Y, Kishikawa Y, Hanada Y, Yamada M, Kakuma T, Kawahara H, Nishi A (2016)
480 Long-term citalopram treatment alters the stress responses of the cortical dopamine and
481 noradrenaline systems: the role of cortical 5-HT1A receptors. Int J Neuropsychopharmacol.
482 Kawahara Y, Kaneko F, Yamada M, Kishikawa Y, Kawahara H, Nishi A (2013) Food reward-sensitive
483 interaction of ghrelin and opioid receptor pathways in mesolimbic dopamine system.
484 Neuropharmacology 67:395-402.

485 Kuroiwa M, Hamada M, Hieda E, Shuto T, Sotogaku N, Flajolet M, Snyder GL, Hendrick JP, Fienberg
486 A, Nishi A (2012) Muscarinic receptors acting at pre- and post-synaptic sites differentially
487 regulate dopamine/DARPP-32 signaling in striatonigral and striatopallidal neurons.
488 Neuropharmacology 63:1248-1257.
489 Lee KW, Westin L, Kim J, Chang JC, Oh YS, Amreen B, Gresack J, Flajolet M, Kim D, Aperia A, Kim
490 Y, Greengard P (2015) p11 regulates the surface localization of mGluR5. Mol Psychiatry
491 20:1485.
492 Medrihan L, Sagi Y, Inde Z, Krupa O, Daniels C, Peyrache A, Greengard P (2017) Initiation of
493 Behavioral Response to Antidepressants by Cholecystokinin Neurons of the Dentate Gyrus.
494 Neuron 95:564-576.e564.
495 Milosevic A, Liebmann T, Knudsen M, Schintu N, Svenningsson P, Greengard P (2017) Cell- and
496 region-specific expression of depression-related protein p11 (S100a10) in the brain. J Comp
497 Neurol 525:955-975.
498 Oh YS, Gao P, Lee KW, Ceglia I, Seo JS, Zhang X, Ahn JH, Chait BT, Patel DJ, Kim Y, Greengard P
499 (2013) SMARCA3, a chromatin-remodeling factor, is required for p11-dependent antidepressant
500 action. Cell 152:831-843.
501 Paxinos G, Franklin KB (2001) Mouse brain in stereotaxic coordinates, 2nd Edition. San Diego:
502 Academic Press.
503 Russo SJ, Nestler EJ (2013) The brain reward circuitry in mood disorders. Nat Rev Neurosci
504 14:609-625.
505 Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N (2012) Identification
506 of the cortical neurons that mediate antidepressant responses. Cell 149:1152-1163.
507 Seo JS, Zhong P, Liu A, Yan Z, Greengard P (2017a) Elevation of p11 in lateral habenula mediates
508 depression-like behavior. Mol Psychiatry.
509 Seo JS, Wei J, Qin L, Kim Y, Yan Z, Greengard P (2017b) Cellular and molecular basis for
510 stress-induced depression. Mol Psychiatry 22:1440-1447.
511 Shelton RC, Tomarken AJ (2001) Can recovery from depression be achieved? Psychiatr Serv

52:1469-1478.

Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P (2013) p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci 14:673-680.

Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P (2006) Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311:77-80.

Thanos PK, Malave L, Delis F, Mangine P, Kane K, Grunseich A, Vitale M, Greengard P, Volkow ND (2016) Knockout of p11 attenuates the acquisition and reinstatement of cocaine conditioned place preference in male but not in female mice. Synapse 70:293-301.

Tourino C, Valjent E, Ruiz-Medina J, Herve D, Ledent C, Valverde O (2012) The orphan receptor GPR3 modulates the early phases of cocaine reinforcement. Br J Pharmacol 167:892-904.

Virk MS, Sagi Y, Medrihan L, Leung J, Kaplitt MG, Greengard P (2016) Opposing roles for serotonin in cholinergic neurons of the ventral and dorsal striatum. Proc Natl Acad Sci U S A 113:734-739.

Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P, Greengard P (2009) Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci 29:1937-1946.

Warner-Schmidt JL, Schmidt EF, Marshall JJ, Rubin AJ, Arango-Lievano M, Kaplitt MG, Ibanez-Tallon I, Heintz N, Greengard P (2012) Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. Proc Natl Acad Sci U S A 109:11360-11365.

Williams MJ, Adinoff B (2008) The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 33:1779-1797.

Witten IB, Lin SC, Brodsky M, Prakash R, Diester I, Anikeeva P, Gradinaru V, Ramakrishnan C, Deisseroth K (2010) Cholinergic interneurons control local circuit activity and cocaine conditioning. Science 330:1677-1681.

Wonnacott S, Kaiser S, Mogg A, Soliakov L, Jones IW (2000) Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol 393:51-58.

Figure legends

Figure 1. The dopamine response to rewarding stimuli in the NAc and PFC of constitutive p11 KO mice.

(**a,b**) Representative location of a microdialysis probe placed in the mouse NAc (**a**) and PFC (**b**) (Paxinos and Franklin, 2001). The position of dialysis membrane is indicated with yellow color. (**c-h**) The effects of cocaine infusion (1 μM) into the NAc (**c**) or PFC (**f**), exposure to palatable food (**d,g**), and exposure to female mice (**e,h**) on the extracellular levels of dopamine (DA) in the NAc (**c,d,e**) and PFC (**f,g,h**) of wild-type (WT) and constitutive p11 KO mice. The DA levels were determined with *in vivo* microdialysis. The basal values for each group were obtained as the average of three stable baseline samples, and all values are calculated as a percentage of the basal values within the same group (100%). Data represent mean ± S.E.M. *p<0.05, ** p<0.01, ***p<0.001 vs. WT mice; two-way ANOVA and Bonferroni multiple comparison test. $^{\dagger}p$<0.05, $^{\dagger\dagger}p$<0.01, $^{\dagger\dagger\dagger}p$<0.001 vs. the basal levels of dopamine in the same group. The number of mice is indicated in parentheses.

Figure 2. The dopamine response to cocaine infusion in the NAc in constitutive p11 KO mice is restored by nicotinic or muscarinic receptor stimulation in the NAc.

Effects of local infusion of cocaine (1 μM) and/or nicotine (1 μM) (**a**) or cocaine (1 μM) and/or non-selective muscarinic receptor agonist, oxotremorine (0.1 μM) (**b**) into the NAc on the extracellular levels of dopamine (DA) in the NAc of constitutive p11 KO mice. The dose of nicotine or oxotremorine without effects on the dopamine levels was used. Data for cocaine infusion alone were reproduced from Fig. 1a for comparison. The basal values for each group were obtained as the average of three stable baseline samples, and all values are calculated as a percentage of the basal values within the same group (100%). Data represent mean ± S.E.M. ** p<0.01, ***p<0.001 vs. the cocaine group; two-way ANOVA and Bonferroni multiple comparison test. $^{\dagger}p$<0.05, $^{\dagger\dagger\dagger}p$<0.001 vs. the basal levels of dopamine in the same group. The number of mice is indicated in parentheses under each experimental condition.

Figure 3. The dopamine response to rewarding stimuli in the NAc of ChAT-p11 conditional

knockout (cKO) mice.

The effects of cocaine infusion (1 μM) into the NAc (**a**), exposure to palatable food (**b**), and exposure to female mice (**c**) on the extracellular levels of dopamine (DA) in the NAc of wild-type (WT; ChAT-Cre$^{-/-}$ p11$^{flox/flox}$) and ChAT-p11 cKO (ChAT-Cre^{+} p11$^{flox/flox}$) mice. The basal values for each group were obtained as the average of three stable baseline samples, and all values are calculated as a percentage of the basal values within the same group (100%). Data represent mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 vs. WT mice; two-way ANOVA and Bonferroni multiple comparison test. $^{\dagger}p$<0.05, $^{\dagger\dagger}p$<0.01, $^{\dagger\dagger\dagger}p$<0.001 vs. the basal levels of dopamine in the same group. The number of mice is indicated in parentheses.

Figure 4. Overexpression of p11 in ChAT cells of the NAc restores the dopamine response to rewarding stimuli in ChAT p11 cKO mice.

(**a**) Immunohistochemical detection of RFP (red) and p11 (green) in the NAc of ChAT-p11 cKO mice injected with p11 overexpressing virus [*AAV-loxP-RFP/stop-loxP-p11,* (*AAV-p11*)] into the NAc. RFP is expressed in ChAT-Cre$^{-/-}$ cells, and p11 was expressed in ChAT-Cre^{+} cells. In images with low magnification (left panel), RFP-positive area in the shell of the NAc corresponds to the area of viral injection. In images with high magnification (right panel), p11 is overexpressed in RFP-negative neurons. Arrows indicate cells overexpressing p11. (**b**) Immunohistochemical detection of RFP (red), YFP (green) and ChAT (blue) in the NAc of ChAT-p11 cKO mice injected with control virus [*AAV-loxP-RFP/stop-loxP-YFP* (*AAV-YFP*)]. RFP was expressed in ChAT-Cre$^{-/-}$ cells, and YFP was expressed in ChAT-Cre^{+} cells. YFP expression overlapped with ChAT staining. Arrow indicates ChAT-positive cholinergic interneurons expressing YFP. (**c,d,e**) The effects of cocaine infusion (1 μM) into the NAc (**c**), exposure to palatable food (**d**), and exposure to female mice (**e**) on the extracellular levels of dopamine (DA) in the NAc of ChAT-p11 cKO mice injected with control (AAV-YFP) or p11 overexpressing (AAV-p11) virus. The basal values for each group were obtained as the average of three stable baseline samples, and all values are calculated as a percentage of the basal values within the same group (100%). Data represent mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 vs. ChAT-p11 cKO mice

with control virus injection; two-way ANOVA and Bonferroni multiple comparison test. $^{\dagger}p<0.05$, $^{\dagger\dagger}p<0.01$, $^{\dagger\dagger\dagger}p<0.001$ vs. the basal levels of dopamine in the same group. The number of mice is indicated in parentheses.

Figure 5. The ACh responses to cocaine infusion in the NAc of ChAT-p11 cKO mice.

The extracellular levels of ACh in the NAc were measured with *in vivo* microdialysis after infusion of cocaine (1 μM) into the NAc of wild-type (WT; ChAT-Cre$^{-/-}$ p11$^{flox/flox}$) and ChAT-p11 cKO (ChAT-Cre^{+} p11$^{flox/flox}$) mice. The basal values for each group were obtained as the average of six stable baseline samples, and all values are calculated as a percentage of the basal values within the same group (100%). Data represent mean ± S.E.M. $^{*}p<0.05$ vs. WT mice; two-way ANOVA and Bonferroni multiple comparison test. $^{\dagger}p<0.05$, $^{\dagger\dagger}p<0.01$, $^{\dagger\dagger\dagger}p<0.001$ vs. the basal levels of ACh in the same group. The number of mice is indicated in parentheses under each experimental condition.

Figure 6. Activation of ChAT cells in the NAc using a chemogenetic technique restores the dopamine response in ChAT p11 cKO mice.

(**a**) Immunohistochemical detection of mCherry (red) and ChAT (green) in the NAc of ChAT-p11 cKO mice injected with Gs-DREADD virus [*AAV-DIO-rM3D(Gs)-mCherry* (*AAV-rM3D(Gs)*)] into the NAc. In images with low magnification (left panel), mCherry-positive cells are aparsely dstributted in the NAc (arrow head). In images with high magnification (right panel), mCherry is expressed in ChAT-positive cholinergic interneurons. Arrows indicate ChAT-positive cholinergic interneurons expressing rM3D(Gs). (**b**) The effects of clozapine N-oxide (CNO) infusion at 3 or 10 μM into the NAc on the extracellular levels of dopamine (DA) in the NAc of ChAT-p11 cKO mice injected with control [*AAV-DIO-mCherry* (*AAV-mCherry*)] or Gs-DREADD virus. The DA levels were determined as the average of those at 40, 60 and 80 min of CNO infusion. Data represent mean ± S.E.M. $^{**}p<0.01$; one-way ANOVA and Newman-Keuls multiple comparison test. (**c**) The effects of CNO infusion (3 μM) into the NAc on the cocaine-induced increases in dopamine (DA) in the NAc of ChAT-p11 cKO mice injected with control (*AAV-mCherry*) or Gs-DREADD virus. The basal values for each group were

obtained as the average of three stable baseline samples, and all values are calculated as a percentage of the basal values within the same group (100%). Data represent mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 vs. ChAT-p11 cKO mice with control virus injection; two-way ANOVA and Bonferroni multiple comparison test. $^{\dagger}p$<0.05, $^{\dagger\dagger}p$<0.01, $^{\dagger\dagger\dagger}p$<0.001 vs. the basal levels of dopamine in the same group. The number of mice is indicated in parentheses under each experimental condition.

Figure 7. Inhibition of ChAT cells in the NAc using a chemogenetic technique suppresses the dopamine response in control mice.

Gi-DREADD virus [*AAV-DIO-rM4D(Gi)-mCherry* (*AAV-rM4D(Gi)*)] or control virus [*AAV-DIO-mCherry* (*AAV-mCherry*)] was injected into the NAc of ChAT-Cre mice. The effects of clozapine N-oxide (CNO) infusion (3 μM) into the NAc on the cocaine-induced increases in dopamine (DA) in the NAc were examined. The basal values for each group were obtained as the average of three stable baseline samples, and all values are calculated as a percentage of the basal values within the same group (100%). Data represent mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 vs. ChAT-p11 cKO mice with control virus injection; two-way ANOVA and Bonferroni multiple comparison test. $^{\dagger\dagger}p$<0.01, $^{\dagger\dagger\dagger}p$<0.001 vs. the basal levels of dopamine in the same group. The number of mice is indicated in parentheses under each experimental condition.















Table 1. Basal levels of dopamine, dopamine metabolites and acetylcholine

mouse	brain region	DA (f mol/sample)	DOPAC (p mol/sample)	HVA (p mol/sample)	ACh (f mol/sample)
WT	NAc	41.28 ± 5.47 (22)	5.725 ± 0.592 (21)	12.73 ± 2.49 (15)	nd
p11 KO (constitutive p11 KO)	NAc	42.35 ± 6.31 (17)	5.777 ± 0.917 (16)	13.57 ± 2.47 (9)	nd
WT	PFC	12.00 ± 4.44 (8)	0.894 ± 0.121 (7)	4.863 ± 1.447 (3)	nd
p11 KO (constitutive p11 KO)	PFC	6.35 ± 1.77 (7)	1.020 ± 0.142 (7)	5.143 ± 0.743 (4)	nd
WT (ChAT-cre$^{-/-}$ P11$^{flox/flox}$)	NAc	46.72 ± 9.94 (8)	6.549 ± 1.264 (8)	nd	428.7 ± 75.65 (12)
ChAT p11 cKO (ChAT-cre P11$^{flox/f}$	NAc	64.13 ± 11.63 (8)	6.485 ± 0.857 (8)	nd	557.0 ± 116.6 (8)
ChAT p11 cKO + *AAV-YFP*	NAc	29.19 ± 6.45 (8)	nd	nd	nd
ChAT p11 cKO + *AAV-p11*	NAc	35.35 ± 10.08 (8)	nd	nd	nd
ChAT p11 cKO + *AAV-mCherry*	NAc	54.18 ± 21.21 (6)	nd	nd	nd
ChAT p11 cKO + *AAV-rM3D (Gs)*	NAc	50.77 ± 22.85 (6)	nd	nd	nd
ChAT p11 cKO + *AAV-mCherry*	NAc	117.8 ± 37.19 (8)	nd	nd	nd
ChAT p11 cKO + *AAV-hM4D (Gi)*	NAc	77.90 ± 21.02 (13)	nd	nd	nd

Data represent Mean ± S.E.M. The numbers of experiments are shown in the parentheses.
DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; ACh, acetylcholine; nd, not determined.

Table 2: Statistical analyses for data

Set of data	Type of statistical analysis	Results of statistical analysis	
Figure 1			
c: DA levels in the NAc with cocaine infusion into the NAc			
Two-way ANOVA for WT and p11 KO mice			
group effect	Two-way ANOVA	$F_{(1,\ 120)}$=49.4312	p<0.0001
time effect	Two-way ANOVA	$F_{(9,\ 120)}$=9.4748	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(9,\ 120)}$=4.1100	p=0.0001
c: DA levels in the NAc with cocaine infusion into the NAc (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=1.2	p=0.2351
basal vs. 40 min	mixed linear models	$t_{(54)}$=5.5	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(54)}$=6.54	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(54)}$=7.04	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(54)}$=6.53	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(54)}$=5.23	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(54)}$=4.39	p<0.0001
c: DA levels in the NAc with cocaine infusion into the NAc (p11 KO mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=-0.69	p=0.4942
basal vs. 40 min	mixed linear models	$t_{(54)}$=0.3	p=0.7639
basal vs. 60 min	mixed linear models	$t_{(54)}$=1.54	p=0.1286
basal vs. 80 min	mixed linear models	$t_{(54)}$=1.79	p=0.0783
basal vs. 100 min	mixed linear models	$t_{(54)}$=2.19	p=0.0326
basal vs. 120 min	mixed linear models	$t_{(54)}$=3.78	p=0.0004
basal vs. 140 min	mixed linear models	$t_{(54)}$=2.86	p=0.0059
d: DA levels in the NAc with exposure to palatable food			
Two-way ANOVA for WT and p11 KO mice			
group effect	Two-way ANOVA	$F_{(1,\ 120)}$=37.1184	p<0.0001
time effect	Two-way ANOVA	$F_{(9,\ 120)}$=3.4984	p=0.0007
group-time interaction	Two-way ANOVA	$F_{(9,\ 120)}$=2.3706	p=0.0167
d: DA levels in the NAc with exposure to palatable food (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=2.08	p=0.0421
basal vs. 40 min	mixed linear models	$t_{(54)}$=4.42	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(54)}$=5.64	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(54)}$=4.7	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(54)}$=3.15	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(54)}$=2.71	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(54)}$=2.23	p<0.0001
d: DA levels in the NAc with exposure to palatable food (p11 KO mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=1.15	p=0.2544
basal vs. 40 min	mixed linear models	$t_{(54)}$=2.03	p=0.0475
basal vs. 60 min	mixed linear models	$t_{(54)}$=1.72	p=0.0911
basal vs. 80 min	mixed linear models	$t_{(54)}$=-0.07	p=0.9414
basal vs. 100 min	mixed linear models	$t_{(54)}$=-1.7	p=0.095
basal vs. 120 min	mixed linear models	$t_{(54)}$=-0.72	p=0.4769
basal vs. 140 min	mixed linear models	$t_{(54)}$=-0.74	p=0.464
e: DA levels in the NAc with exposure to female mice			
Two-way ANOVA for WT and p11 KO mice			
group effect	Two-way ANOVA	$F_{(1,\ 80)}$=39.2674	p<0.0001
time effect	Two-way ANOVA	$F_{(7,\ 80)}$=7.0594	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(7,\ 80)}$=3.7936	p=0.0013
e: DA levels in the NAc with exposure to female mice (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(35)}$=5.69	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(35)}$=8.36	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(35)}$=5.29	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(35)}$=3.39	p=0.0017
basal vs. 100 min	mixed linear models	$t_{(35)}$=3.06	p=0.0042
e: DA levels in the NAc with exposure to female mice (p11 KO mice)			
basal vs. 20 min	mixed linear models	$t_{(35)}$=0.33	p=0.7429
basal vs. 40 min	mixed linear models	$t_{(35)}$=2.21	p=0.0335
basal vs. 60 min	mixed linear models	$t_{(35)}$=0.46	p=0.6483
basal vs. 80 min	mixed linear models	$t_{(35)}$=0.17	p=0.865
basal vs. 100 min	mixed linear models	$t_{(35)}$=-1.9	p=0.5526
f: DA levels in the PFC with cocaine infusion			
Two-way ANOVA for WT and p11 KO mice			
group effect	Two-way ANOVA	$F_{(1,\ 120)}$=0.00970	p=0.7560
time effect	Two-way ANOVA	$F_{(9,\ 120)}$=8.8283	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(9,\ 120)}$=0.00895	p=0.9997
f: DA levels in the PFC with cocaine infusion into the PFC (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=0.9	p=0.3719
basal vs. 40 min	mixed linear models	$t_{(54)}$=3.04	p=0.0037
basal vs. 60 min	mixed linear models	$t_{(54)}$=4.29	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(54)}$=5.3	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(54)}$=5.98	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(54)}$=4.86	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(54)}$=4.23	p<0.0001
f: DA levels in the PFC with cocaine infusion into the PFC (p11 KO mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=1.06	p=0.2933
basal vs. 40 min	mixed linear models	$t_{(54)}$=3.26	p=0.0019
basal vs. 60 min	mixed linear models	$t_{(54)}$=4.61	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(54)}$=5.4	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(54)}$=4.94	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(54)}$=5.18	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(54)}$=5.09	p<0.0001
g: DA levels in the PFC with exposure to palatable food			
Two-way ANOVA for WT and p11 KO mice			
group effect	Two-way ANOVA	$F_{(1,\ 120)}$=0.0733	p=0.7870
time effect	Two-way ANOVA	$F_{(9,\ 120)}$=11.4806	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(9,\ 120)}$=0.1100	p=0.9994
g: DA levels in the PFC with exposure to palatable food (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=4.23	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(54)}$=5.92	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(54)}$=4.67	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(54)}$=4.22	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(54)}$=3.99	p=0.0002
basal vs. 120 min	mixed linear models	$t_{(54)}$=2.54	p=0.0139
basal vs. 140 min	mixed linear models	$t_{(54)}$=1.9	p=0.0631
g: DA levels in the PFC with exposure to palatable food (p11 KO mice)			
basal vs. 20 min	mixed linear models	$t_{(54)}$=4.55	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(54)}$=5.86	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(54)}$=5.41	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(54)}$=4.84	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(54)}$=4.42	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(54)}$=3.37	p=0.0014
basal vs. 140 min	mixed linear models	$t_{(54)}$=3.14	p=0.0028
h: DA levels in the PFC with exposure to female mice			
Two-way ANOVA for WT and p11 KO mice			
group effect	Two-way ANOVA	$F_{(1,\ 80)}$=0.1875	p=0.6661
time effect	Two-way ANOVA	$F_{(7,\ 80)}$=12.2601	p<0.0001

group-time interaction	Two-way ANOVA	$F_{(7, 80)}$=0.7459	p=0.6339
h: DA levels in the PFC with exposure to female mice (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(35)}$=5.76	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(35)}$=7.14	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(35)}$=3.72	p=0.0007
basal vs. 80 min	mixed linear models	$t_{(35)}$=1.28	p=0.2092
basal vs. 100 min	mixed linear models	$t_{(35)}$=-0.05	p=0.9614
h: DA levels in the PFC with exposure to female mice (p11 KO mice)			
basal vs. 20 min	mixed linear models	$t_{(35)}$=3.34	p=0.002
basal vs. 40 min	mixed linear models	$t_{(35)}$=6.59	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(35)}$=3.54	p=0.0011
basal vs. 80 min	mixed linear models	$t_{(35)}$=1.89	p=0.0675
basal vs. 100 min	mixed linear models	$t_{(35)}$=2.16	p=0.0373
Figure 2			
a: DA levels in the NAc with cocaine and/or nicotine infusion in p11 KO mice			
Two-way ANOVA for cocaine and cocaine + nicotine infusion			
group effect	Two-way ANOVA	$F_{(1, 120)}$=45.9468	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 120)}$=9.0389	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(8, 120)}$=3.0465	p=0.0026
Two-way ANOVA for nicotine and cocaine + nicotine infusion			
group effect	Two-way ANOVA	$F_{(1, 110)}$=83.0855	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 110)}$=4.9164	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(8, 110)}$=5.2703	p<0.0001
a: DA levels in the NAc with cocaine and nicotine infusion in p11 KO mice			
basal vs. 20 min	mixed linear models	$t_{(64)}$=1.32	p=0.1932
basal vs. 40 min	mixed linear models	$t_{(64)}$=4.37	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(64)}$=6.19	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(64)}$=6.05	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(64)}$=5.03	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(64)}$=5.53	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(64)}$=5.46	p<0.0001
a: DA levels in the NAc with nicotine infusion in p11 KO mice			
basal vs. 20 min	mixed linear models	$t_{(45)}$=-0.46	p=0.6509
basal vs. 40 min	mixed linear models	$t_{(45)}$=0.09	p=0.9282
basal vs. 60 min	mixed linear models	$t_{(45)}$=0.21	p=0.8359
basal vs. 80 min	mixed linear models	$t_{(45)}$=-0.03	p=0.9802
basal vs. 100 min	mixed linear models	$t_{(45)}$=-0.07	p=0.9407
basal vs. 120 min	mixed linear models	$t_{(45)}$=0.08	p=0.9383
basal vs. 140 min	mixed linear models	$t_{(45)}$=-1.49	p=0.1437
b: DA levels in the NAc with cocaine and/or oxotremorine infusion in p11 KO mice			
Two-way ANOVA for cocaine and cocaine + oxotremorine infusion			
group effect	Two-way ANOVA	$F_{(1, 120)}$=89.7480	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 120)}$=13.8003	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(8, 120)}$=5.6135	p<0.0001
Two-way ANOVA for oxotremorine and cocaine + oxotremorine infusion			
group effect	Two-way ANOVA	$F_{(1, 110)}$=72.5608	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 110)}$=8.88318	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(8, 110)}$=5.3849	p<0.0001
b: DA levels in the NAc with cocaine and oxotremorine infusion in p11 KO mice			
basal vs. 20 min	mixed linear models	$t_{(64)}$=1.72	p=0.0907
basal vs. 40 min	mixed linear models	$t_{(64)}$=6.21	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(64)}$=7.6	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(64)}$=8.13	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(64)}$=9.28	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(64)}$=7.82	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(64)}$=7.47	p<0.0001
b: DA levels in the NAc with oxotremorine infusion in p11 KO mice			
basal vs. 20 min	mixed linear models	$t_{(45)}$=1.25	p=0.2171
basal vs. 40 min	mixed linear models	$t_{(45)}$=1.42	p=0.1612
basal vs. 60 min	mixed linear models	$t_{(45)}$=2.26	p=0.029
basal vs. 80 min	mixed linear models	$t_{(45)}$=1.37	p=0.1774
basal vs. 100 min	mixed linear models	$t_{(45)}$=0.75	p=0.4567
basal vs. 120 min	mixed linear models	$t_{(45)}$=1.88	p=0.0661
basal vs. 140 min	mixed linear models	$t_{(45)}$=0.66	p=0.5144
Figure 3			
a: DA levels in the NAc with cocaine infusion			
Two-way ANOVA for WT and ChAT-p11 cKO mice			
group effect	Two-way ANOVA	$F_{(1, 140)}$=108.3406	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 140)}$=21.5972	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(8, 140)}$=6.8674	p<0.0001
a: DA levels in the NAc with cocaine infusion into the NAc (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=2.24	p=0.0288
basal vs. 40 min	mixed linear models	$t_{(63)}$=6.09	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(63)}$=8.34	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(63)}$=9.09	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(63)}$=9	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(63)}$=9.97	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(63)}$=9.71	p<0.0001
a: DA levels in the NAc with cocaine infusion into the NAc (ChAT-p11 cKO mice)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=0.28	p=0.7771
basal vs. 40 min	mixed linear models	$t_{(63)}$=4.04	p=0.0001
basal vs. 60 min	mixed linear models	$t_{(63)}$=4.2	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(63)}$=4.44	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(63)}$=4.82	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(63)}$=4.84	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(63)}$=5.38	p<0.0001
b: DA levels in the NAc with exposure to palatable food			
Two-way ANOVA for WT and ChAT-p11 cKO mice			
group effect	Two-way ANOVA	$F_{(1, 140)}$=29.2503	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 140)}$=2.5700	p=0.0091
group-time interaction	Two-way ANOVA	$F_{(8, 140)}$=3.0056	p=0.0026
b: DA levels in the NAc with exposure to palatable food (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=5.14	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(63)}$=6.24	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(63)}$=2.91	p=0.005
basal vs. 80 min	mixed linear models	$t_{(63)}$=1.95	p=0.0554
basal vs. 100 min	mixed linear models	$t_{(63)}$=1.96	p=0.0541
basal vs. 120 min	mixed linear models	$t_{(63)}$=1.08	p=0.284
basal vs. 140 min	mixed linear models	$t_{(63)}$=1.77	p=0.0816
b: DA levels in the NAc with exposure to palatable food (ChAT-p11 cKO mice)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=-0.43	p=0.6675
basal vs. 40 min	mixed linear models	$t_{(63)}$=-0.31	p=0.7584
basal vs. 60 min	mixed linear models	$t_{(63)}$=-0.45	p=0.6577
basal vs. 80 min	mixed linear models	$t_{(63)}$=-0.72	p=0.4734
basal vs. 100 min	mixed linear models	$t_{(63)}$=0.13	p=0.9005
basal vs. 120 min	mixed linear models	$t_{(63)}$=0.2	p=0.8398
basal vs. 140 min	mixed linear models	$t_{(63)}$=-0.31	p=0.7576

c: DA levels in the NAc with exposure to female mice			
Two-way ANOVA for WT and ChAT-p11 cKO mice			
group effect	Two-way ANOVA	$F_{(1, 112)}$=31.1748	p<0.0001
time effect	Two-way ANOVA	$F_{(7, 112)}$=6.5263	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(7, 112)}$=4.9259	p<0.0001
c: DA levels in the NAc with exposure to female mice (WT mice)			
basal vs. 20 min	mixed linear models	$t_{(49)}$=5	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(49)}$=6.39	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(49)}$=3.29	p=0.0018
basal vs. 80 min	mixed linear models	$t_{(49)}$=1.8	p=0.0785
basal vs. 100 min	mixed linear models	$t_{(49)}$=1.79	p=0.0802
c: DA levels in the NAc with exposure to female mice (ChAT-p11 cKO mice)			
basal vs. 20 min	mixed linear models	$t_{(49)}$=0.37	p=0.7103
basal vs. 40 min	mixed linear models	$t_{(49)}$=1.12	p=0.2681
basal vs. 60 min	mixed linear models	$t_{(49)}$=2.51	p=0.0153
basal vs. 80 min	mixed linear models	$t_{(49)}$=1.24	p=0.2202
basal vs. 100 min	mixed linear models	$t_{(49)}$=0.02	p=0.9862
Figure 4			
c: DA levels in the NAc with cocaine infusion in ChAT-p11 cKO mice injected with *AAV-p11* or *AAV-YFP*			
Two-way ANOVA for *AAV-p11* and *AAV-YFP*			
group effect	Two-way ANOVA	$F_{(1, 140)}$=39.4565	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 140)}$=8.6938	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(8, 140)}$=2.6737	p<0.0001
c: DA levels in the NAc with cocaine infusion into the NAc (p11 cKO + *AAV-YFP*)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=0.17	p=0.8632
basal vs. 40 min	mixed linear models	$t_{(63)}$=4.83	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(63)}$=5.37	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(63)}$=5.71	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(63)}$=6.91	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(63)}$=5.5	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(63)}$=4.29	p<0.0001
c: DA levels in the NAc with cocaine infusion into the NAc (p11 cKO + *AAV-p11*)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=0.91	p=0.3647
basal vs. 40 min	mixed linear models	$t_{(63)}$=4.15	p=0.0001
basal vs. 60 min	mixed linear models	$t_{(63)}$=5.59	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(63)}$=6.41	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(63)}$=6.22	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(63)}$=5.92	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(63)}$=4.92	p<0.0001
d: DA levels in the NAc with exposure to palatable food in ChAT-p11 cKO mice injected with *AAV-p11* or *AAV-YFP*			
Two-way ANOVA for *AAV-p11* and *AAV-YFP*			
group effect	Two-way ANOVA	$F_{(1, 140)}$=57.9163	p<0.0001
time effect	Two-way ANOVA	$F_{(8, 140)}$=3.8107	p=0.0003
group-time interaction	Two-way ANOVA	$F_{(8, 140)}$=3.4534	p=0.0007
d: DA levels in the NAc with exposure to palatable food (p11 cKO + *AAV-YFP*)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=-0.54	p=0.5909
basal vs. 40 min	mixed linear models	$t_{(63)}$=0.75	p=0.4536
basal vs. 60 min	mixed linear models	$t_{(63)}$=-2.08	p=0.0412
basal vs. 80 min	mixed linear models	$t_{(63)}$=-2.62	p=0.0111
basal vs. 100 min	mixed linear models	$t_{(63)}$=-2.21	p=0.0308
basal vs. 120 min	mixed linear models	$t_{(63)}$=-1.85	p=0.0695
basal vs. 140 min	mixed linear models	$t_{(63)}$=-3.65	p=0.0005
d: DA levels in the NAc with exposure to palatable food (p11 cKO + *AAV-p11*)			
basal vs. 20 min	mixed linear models	$t_{(63)}$=4.45	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(63)}$=6.65	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(63)}$=3.76	p=0.0004
basal vs. 80 min	mixed linear models	$t_{(63)}$=3.66	p=0.0005
basal vs. 100 min	mixed linear models	$t_{(63)}$=2.07	p=0.0424
basal vs. 120 min	mixed linear models	$t_{(63)}$=2.2	p=0.0315
basal vs. 140 min	mixed linear models	$t_{(63)}$=0.98	p=0.3308
e: DA levels in the NAc with exposure to female mice in ChAT-p11 cKO mice injected with *AAV-p11* or *AAV-YFP*			
Two-way ANOVA for *AAV-p11* and *AAV-YFP*			
group effect	Two-way ANOVA	$F_{(1, 112)}$=25.2729	p<0.0001
time effect	Two-way ANOVA	$F_{(7, 112)}$=5.4068	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(7, 112)}$=2.5674	p=0.0172
e: DA levels in the NAc with exposure to female mice (p11 cKO + *AAV-YFP*)			
basal vs. 20 min	mixed linear models	$t_{(49)}$=0.62	p=0.5353
basal vs. 40 min	mixed linear models	$t_{(49)}$=1.92	p=0.0608
basal vs. 60 min	mixed linear models	$t_{(49)}$=0.25	p=0.8038
basal vs. 80 min	mixed linear models	$t_{(49)}$=-1.14	p=0.2615
basal vs. 100 min	mixed linear models	$t_{(49)}$=-0.64	p=0.5276
e: DA levels in the NAc with exposure to female mice (p11 cKO + *AAV-p11*)			
basal vs. 20 min	mixed linear models	$t_{(49)}$=5.9	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(49)}$=5.69	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(49)}$=3.21	p=0.0023
basal vs. 80 min	mixed linear models	$t_{(49)}$=2.05	p=0.0458
basal vs. 100 min	mixed linear models	$t_{(49)}$=2.38	p=0.0212
Figure 5			
a: ACh levels in the NAc with cocaine infusion			
Two-way ANOVA for WT and ChAT-p11 cKO mice			
group effect	Two-way ANOVA	$F_{(1,324}$ =35.3923	p<0.0001
time effect	Two-way ANOVA	$F_{(17,324}$ =0.9289	p=0.5400
group-time interaction	Two-way ANOVA	$F_{(17, 324)}$=1.7341	p=0.0358
a: ACh levels in the NAc with cocaine infusion into the NAc (WT mice)			
basal vs. 10 min	mixed linear models	$t_{(187)}$=-0.14	p=0.8895
basal vs. 20 min	mixed linear models	$t_{(187)}$=4.07	p<0.0001
basal vs. 30 min	mixed linear models	$t_{(187)}$=2.86	p=0.0047
basal vs. 40 min	mixed linear models	$t_{(187)}$=2.65	p=0.0087
basal vs. 50 min	mixed linear models	$t_{(187)}$=3.73	p=0.0003
basal vs. 60 min	mixed linear models	$t_{(187)}$=3.55	p=0.0005
basal vs. 70 min	mixed linear models	$t_{(187)}$=4.11	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(187)}$=3.23	p=0.0015
basal vs. 90 min	mixed linear models	$t_{(187)}$=2.53	p=0.0123
basal vs. 100 min	mixed linear models	$t_{(187)}$=2.92	p=0.0039
basal vs. 110 min	mixed linear models	$t_{(187)}$=2.76	p=0.0063
basal vs. 120 min	mixed linear models	$t_{(187)}$=3.29	p=0.0012
a: ACh levels in the NAc with cocaine infusion into the NAc (ChAT-p11 cKO mice)			
basal vs. 10 min	mixed linear models	$t_{(119)}$=-0.55	p=0.5808
basal vs. 20 min	mixed linear models	$t_{(119)}$=-1.2	p=0.2334
basal vs. 30 min	mixed linear models	$t_{(119)}$=-1.98	p=0.0502
basal vs. 40 min	mixed linear models	$t_{(119)}$=-2.38	p=0.0191
basal vs. 50 min	mixed linear models	$t_{(119)}$=-0.46	p=0.6487
basal vs. 60 min	mixed linear models	$t_{(119)}$=0.21	p=0.835
basal vs. 70 min	mixed linear models	$t_{(119)}$=-0.44	p=0.6587
basal vs. 80 min	mixed linear models	$t_{(119)}$=-1.03	p=0.3053
basal vs. 90 min	mixed linear models	$t_{(119)}$=-1.36	p=0.1767

basal vs. 100 min	mixed linear models	$t_{(119)}$=-0.44	p=0.6627
basal vs. 110 min	mixed linear models	$t_{(119)}$=0.07	p=0.9468
basal vs. 120 min	mixed linear models	$t_{(119)}$=0.39	p=0.6987
Figure 6			
b: DA levels in the NAc with CNO infusion in ChAT-p11 cKO mice injected with *AAV-rM3D* or *AAV-mCherry*	One-way ANOVA	$F_{(3, 20)}$=7.643	p=0.0014
AAV-mCherry/CNO 10 µM vs *AAV-rM3D*/CNO 10 µM	Newman–Keuls pos hoc test		p<0.01
AAV-rM3D/CNO 3 µM vs *AAV-rM3D*/CNO 10 µM	Newman–Keuls pos hoc test		p<0.01
c: DA levels in the NAc with cocaine or CNO + cocaine infusion in ChAT-p11 cKO mice injected with *AAV-rM3D* or *AAV-mCherry*			
Two-way ANOVA for *AAV-rM3D*/CNO + cocaine or *AAV-mCherry*/CNO + cocaine			
group effect	Two-way ANOVA	$F_{(1, 100)}$=94.7020	p<0.0001
time effect	Two-way ANOVA	$F_{(9, 100)}$=23.4516	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(9, 100)}$=5.7876	p<0.0001
Two-way ANOVA for *AAV-rM3D*/CNO + cocaine or *AAV-rM3D*/cocaine			
group effect	Two-way ANOVA	$F_{(1, 100)}$=106.4829	p<0.0001
time effect	Two-way ANOVA	$F_{(9, 100)}$=15.2109	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(9, 100)}$=6.4710	p<0.0001
c: DA levels in the NAc with CNO + cocaine infusion in ChAT-p11 cKO mice injected with *AAV-rM3D*			
basal vs. 20 min	mixed linear models	$t_{(45)}$=2.53	p=0.015
basal vs. 40 min	mixed linear models	$t_{(45)}$=7.21	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(45)}$=6.78	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(45)}$=7.95	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(45)}$=8.68	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(45)}$=7.87	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(45)}$=10.11	p<0.0001
c: DA levels in the NAc with CNO + cocaine infusion in ChAT-p11 cKO mice injected with *AAV-mCherry*			
basal vs. 20 min	mixed linear models	$t_{(45)}$=0.64	p=0.5243
basal vs. 40 min	mixed linear models	$t_{(45)}$=3.98	p=0.0002
basal vs. 60 min	mixed linear models	$t_{(45)}$=6.48	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(45)}$=5.56	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(45)}$=6.59	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(45)}$=6.36	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(45)}$=6.33	p<0.0001
c: DA levels in the NAc with cocaine infusion in ChAT-p11 cKO mice injected with *AAV-rM3D*			
basal vs. 20 min	mixed linear models	$t_{(45)}$=-0.45	p=0.6554
basal vs. 40 min	mixed linear models	$t_{(45)}$=2.43	p=0.0192
basal vs. 60 min	mixed linear models	$t_{(45)}$=2.96	p=0.0049
basal vs. 80 min	mixed linear models	$t_{(45)}$=1.85	p=0.0709
basal vs. 100 min	mixed linear models	$t_{(45)}$=1.59	p=0.1184
basal vs. 120 min	mixed linear models	$t_{(45)}$=2.56	p=0.014
basal vs. 140 min	mixed linear models	$t_{(45)}$=2.99	p=0.0045
c: DA levels in the NAc with cocaine infusion in ChAT-p11 cKO mice injected with *AAV-mCherry*			
basal vs. 20 min	mixed linear models	$t_{(45)}$=0.81	p=0.4199
basal vs. 40 min	mixed linear models	$t_{(45)}$=0.81	p=..0002
basal vs. 60 min	mixed linear models	$t_{(45)}$=0.81	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(45)}$=0.81	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(45)}$=0.81	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(45)}$=0.81	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(45)}$=0.81	p<0.0001
Figure 7			
a: DA levels in the NAc with cocaine or CNO + cocaine infusion in ChAT-p11 cKO mice injected with *AAV-hM4D* or *AAV-mCherry*			
Two-way ANOVA for *AAV-hM4D*/CNO + cocaine or *AAV-mCherry*/CNO + cocaine			
group effect	Two-way ANOVA	$F_{(1,150)}$=12.3097	p=0.0006
time effect	Two-way ANOVA	$F_{(9,150)}$=17.6639	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(9,150)}$=1.2133	p=0.2908
Two-way ANOVA for *AAV-hM4D*/CNO + cocaine or *AAV-hM4D*/cocaine			
group effect	Two-way ANOVA	$F_{(1,220)}$=32.4559	p<0.0001
time effect	Two-way ANOVA	$F_{(9,220)}$=14.3297	p<0.0001
group-time interaction	Two-way ANOVA	$F_{(9,220)}$=1.7342	p=0.0826
c: DA levels in the NAc with CNO + cocaine infusion in ChAT-p11 cKO mice injected with *AAV-hM4D*			
basal vs. 20 min	mixed linear models	$t_{(90)}$=2.68	p=0.0087
basal vs. 40 min	mixed linear models	$t_{(90)}$=4.63	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(90)}$=7.40	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(90)}$=7.17	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(90)}$=6.77	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(90)}$=6.99	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(90)}$=7.22	p<0.0001
c: DA levels in the NAc with CNO + cocaine infusion in ChAT-p11 cKO mice injected with *AAV-mCherry*			
basal vs. 20 min	mixed linear models	$t_{(45)}$=-0.11	p=0.9112
basal vs. 40 min	mixed linear models	$t_{(45)}$=3.79	p=0.0005
basal vs. 60 min	mixed linear models	$t_{(45)}$=6.43	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(45)}$=5.87	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(45)}$=5.20	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(45)}$=5.13	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(45)}$=5.28	p<0.0001
c: DA levels in the NAc with cocaine infusion in ChAT-p11 cKO mice injected with *AAV-hM4D*			
basal vs. 20 min	mixed linear models	$t_{(108)}$=4.40	p<0.0001
basal vs. 40 min	mixed linear models	$t_{(108)}$=7.77	p<0.0001
basal vs. 60 min	mixed linear models	$t_{(108)}$=8.47	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(108)}$=8.23	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(108)}$=8.63	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(108)}$=8.33	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(108)}$=7.47	p<0.0001
c: DA levels in the NAc with cocaine infusion in ChAT-p11 cKO mice injected with *AAV-mCherry*			
basal vs. 20 min	mixed linear models	$t_{(83)}$=0.81	p=0.4199
basal vs. 40 min	mixed linear models	$t_{(83)}$=4.02	p=0.0002
basal vs. 60 min	mixed linear models	$t_{(83)}$=5.64	p<0.0001
basal vs. 80 min	mixed linear models	$t_{(83)}$=6.52	p<0.0001
basal vs. 100 min	mixed linear models	$t_{(83)}$=5.89	p<0.0001
basal vs. 120 min	mixed linear models	$t_{(83)}$=5.89	p<0.0001
basal vs. 140 min	mixed linear models	$t_{(83)}$=6.00	p<0.0001
Table 1			
Basal levels of dopamine, dopamine metabolites and acetylcholine			
NAc DA, WT vs p11 KO	t-test	$t_{(39)}$=0.1283	p=0.8986
NAc DOPAC, WT vs p11 KO	t-test	$t_{(39)}$=0.04948	p=0.9608
NAc HVA, WT vs p11 KO	t-test	$t_{(22)}$=0.2247	p=0.8243
PFC DA, WT vs p11 KO	t-test (Welch's-correction)	$t_{(13)}$=1.183	p=0.2672
PFC DOPAC, WT vs p11 KO	t-test	$t_{(22)}$=0.6739	p=0.5132
PFC HVA, WT vs p11 KO	t-test	$t_{(8)}$=0.1866	p=.8593
NAc DA, WT vs ChAT-p11 cKO	t-test	$t_{(14)}$=1.139	p=0.2739
NAc DOPAC, WT vs ChAT-p11 cKO	t-test	$t_{(14)}$=0.04194	p=0.9671
NAc ACh, WT vs ChAT-p11 cKO	t-test	$t_{(18)}$=0.9686	p=0.3456
NAc DA, ChAT-p11 cKO + *AAV-YFP* vs ChAT-p11 cKO + *AAV-p11*	t-test	$t_{(14)}$=0.5145	p=0.6149
NAc DA, ChAT-p11 cKO + *AAV-mCherry* vs ChAT-p11 cKO + *AAV-rM3D(Gs)*	t-test	$t_{(10)}$=0.1095	p=0.9150
NAc DA, ChAT-p11 cKO + *AAV-mCherry* vs ChAT-p11 cKO + *AAV-hM4D (Gi)*	t-test	$t_{(19)}$=1.011	p=0.3246